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ABSTRACT 
 
A non-invasive in vivo imaging method for NK cell trafficking is essential to gain 
further understanding of the pathogenesis of NK cell mediated immune response to the novel 
cancer treatment strategies, and to discover the homing sites and physiological distribution of 
NK cells. Although human NK cells can be labeled for in vivo imaging, a little is known 
about the murine NK cell labeling and its application in animal models. This study describes 
the isolation and ex-vivo radiolabeling of murine NK cells for the evaluation of cell 
trafficking in an orthotopic model of human lung cancer in mice. 
 
Scid-Tg(FCGR3A)Blt transgenic SCID mice were used to isolate NK cells from 
mouse splenocytes using the CD49b (DX5) MicroBeads positive selection method. The 
purity and viability of the isolated NK cells were confirmed by FACS analysis. Different 
labeling buffers and incubation times were evaluated to optimize 
111
In-oxine labeling 
conditions. Functionality of the radiolabeled NK cell was assessed by 
51
Cr-release assay. We 
evaluated physiological distribution of 
111
In-oxine labeled murine NK cells in normal SCID 
mice and biodistribution in irradiated and non-irradiated SCID mice with orthotopic A549 
human lung tumor lesions. Imaging findings were confirmed by histology.  
 
Results showed that incubation with 0.011 MBq of 
111
In-oxine per million murine NK 
cells in PBS (pH 7.4) for 20-min is the best condition that provides optimum labeling 
efficiency without affecting cell viability and functionality. Physiological distribution in 
normal SCID mice demonstrated NK cells homing mainly in the spleen, while 
111
In released 
from NK cells was excreted via kidneys into urine. Biodistribution studies demonstrated a 
higher lung uptake in orthotopic lung tumor-bearing mice than control mice. In irradiated 
mice, lung tumor uptake of radiolabeled murine NK cells decreased between 24h and 72h 
p.i., which was accompanied by tumor regression, while in non-irradiated mice, radiolabeled 
NK cells were retained in the lung tumor lesions up to 72h p.i. without tumor regression. In 
tumor-bearing mice that were only irradiated but did not receive radiolabeled murine NK 
cells, a high tumor burden was observed at 72h p.i., which indicates that irradiation in 
combination with murine NK cell allocation, but not irradiation alone, induced a remarkable 
anti-tumor effect in the orthotopic A549 lung tumor bearing mouse model.  
 
In conclusion, we describe a method to evaluate murine NK cell trafficking and 
biodistribution, which can be used to determine potential effects of immune-mediated 
therapeutic agents on NK cell biodistribution. 
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INTRODUCTION 
 
Different immune cells, including natural killer (NK) cells, execute key role in cancer 
immunotherapy.
1,2
 Therefore, new cancer treatment strategies that activates immune cells and 
promote infiltration in tumor lesions are being generated. Assessing the in vivo efficacy of 
these immunotherapeutic approaches needs non-invasive and sensitive cell-tracking method. 
Use of radiolabeled immune cells to follow cell trafficking and discover the homing sites may 
facilitate the understanding of the pathogenesis of different immune cell mediated responses 
to the immunotherapeutic strategies. 
Many studies have been published using 
111
In-oxine labeled human lymphocytes
3
 and a few 
studies used labeled human NK cells for in vivo biodistribution studies. Meller et al.
4
 labeled 
human NK cells with 0.05 to 0.1 MBq of 
111
In per million cells, and Brand et al.
5
 labeled 
human NK cells with 0.074 MBq of 
111
In per million cells, for the evaluation of NK cell 
kinetics and biodistribution in renal cell carcinoma patients. In both studies, patients received 
average 5 x 10
8
 NK cells labeled with
 111
In-oxine with tenfold excess of unlabeled NK cells 
for therapy. Whole-body scans were performed from 0.5h to 144h post-transfusion to follow 
cell-trafficking, however cells were evidently detectable up to first 72h. Both studies 
confirmed that allogenic NK cells retain their immune reactivity even after radiolabeling, 
specifically accumulate in the tumor lesions and showed in vivo anti-tumor activity. Matera et 
al.
6
 labeled human adherent NK cells with 0.074 MBq of 
111
In per million cells for the single-
photon emission computed tomography (SPECT) evaluation of migration and homing of NK 
cells in patients with colon carcinoma; authors also compared their differential localization in 
normal and neoplastic liver using 
99m
Tc-phytate. 5 x 10
8
 labeled NK cells administered either 
systemic (intra-venous) or locoregional (intra-arterial) routes to each patient. This study 
showed that locoregionally injected labeled NK cells predominantly localize in the liver 
metastases and these results were consistence with 
99m
Tc-phytate SPECT analysis. Such 
scintigraphic approaches using radiolabeled NK cells may contribute to the optimization of 
immunotherapeutic strategies.  
In all the above mentioned clinical studies investigators ex-vivo enriched and cultivated NK 
cells for 2 weeks using rIL-2 and other lymphokines
7
, which help to obtain a good cell count 
(about 100 fold expansion) of NK cells to be radiolabeled with 37 MBq of 
111
In-oxine for 
scintigraphy studies. However, the main problem with the use of lymphokines activated NK 
cell is their heterogeneous population due to change in the expression of different cell surface 
markers during the cultivation process
8
. Because of these changes expanded NK cells are 
preferably used for adoptive immunotherapy purpose due to its highly activated population. 
However, the use of expanded NK cells for in-vivo imaging of cell trafficking to investigate 
the effect of any immunotherapeutic agent on a specific immune cell could be tricky, since 
the results could be compromised by the change in the expression of cell surface markers 
during cell expansion procedure.  
An interesting study was performed by Frohn et al.
9
 to evaluate if adoptive immunotherapy 
with NK cells could be well tolerated when only highly enriched NK cells is applied without 
ex-vivo expansion. In this feasibility study, 10 cancer patients were repeatedly transfused with 
average 1.02±0.27 x 10
9 
NK cells per transfusion. The transfusion was repeated up to four 
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times after 5-6 weeks. Authors did not observe any serious acute/delayed reaction or allergic 
response and patient results demonstrated a good tolerability. The downside of this 
immunotherapy study was the use of a much higher blood volume (ranged from 10 to 12 L) 
for apheresis procedure in comparison to the studies where ex-vivo expansion of NK cells 
performed before transfusion (ranged from 3 to 4 L). However, this study demonstrated that 
we can use immune cells without ex-vivo expansion, and fortunately, for in-vivo imaging 
(cell-trafficking) studies we require a significantly lower amount of radiolabeled immune 
cells. 
In preclinical setting, we can isolate about 1 million NK cells from each mouse spleen and 
only 0.011 MBq of 
111
In-oxine can be used to label them, since higher 
111
In dose will affect 
cell viability. Moreover, if we want to perform a SPECT imaging study in mouse model then 
relatively higher doses (20-60 MBq) of 
111
In-labeled murine NK cells are required to achieve 
reasonable images, due to low sensitivity of microSPECT camera. Therefore, an enormous 
number of mice would be required to isolate NK cells for a microSPECT imaging study. This 
is the reason why till now no study demonstrated murine NK cell labeling with 
111
In-oxine 
for microSPECT imaging. To overcome this issue, we decided to perform ex-vivo 
biodistribution and gamma counting study, which is a much more sensitive method and 
requires much less animals.  
The 
111
In-oxine complex is a well-known for human lymphocyte labeling and imaging due to 
its long half-life and easy labeling procedure.
15-17
 However, some other PET imaging isotopes 
have also been proposed for human lymphocyte, stem cell and mouse cancer cell labeling that 
includes 
99m
Tc-HMPAO, 
18
F-FDG, 
64
Cu and recently published 
89
Zr, each one has its own 
benefits and drawbacks.
17-20
 Nevertheless, few studies also attempted to specifically image 
human NK cells using indirect approaches that comprise labeling of genetically modified 
human NK cell line NK-92-scFv(FRP5)-zeta with 
18
F-FDG,
21
 and use of 
99m
Tc-anti-CD56 
antibody against human NK cells.
22
 
In the present study, we evaluated the isolation and ex-vivo 
111
In-oxine labeling of murine NK 
cells for monitoring physiological distribution and in-vivo kinetics in an orthotopic model of 
A549 human lung cancer in mice. Results were compared with irradiated mice groups, in 
which autologous NK cells were depleted to avoid the possibility of interference with the 
adoptively transferred NK cells.  
 
MATERIALS AND METHODS 
 
Mice and cell lines 
All animal studies were performed according to Dutch national regulations after approval was 
received from the Institutional Animal Care and Use Committee (IACUC). 
Scid-Tg(FCGR3A)Blt transgenic mice (Charles River Laboratories Inc./ Roche Glycart AG, 
Switzerland) were used (GGO.Nr: IG 11-104) to isolate NK cells. These mice express human 
FcgRIIIA (CD16) positive NK cells as effectors (about 80% of murine NK cells express 
human CD16), allowing a more accurate representation of efficacy via antibody-dependent 
cell–mediated cytotoxicity.
10
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CB17/Icr-Prkdc
scid
/IcrlcoCrl mice (Charles River Laboratories Inc.) were used for 
biodistribution experiments. These mice have T and B-lymphocyte deficiency, but normal 
NK cell activity and radiation sensitivity, providing an appropriate in-vivo microenvironment 
for NK cell trafficking and irradiation experiments. 
Human lung adenocarcinoma A549 cell line and murine lymphoma YAC-1 cell line were 
used for lung tumor growth and the NK cell functionality assay, respectively. Cells were 
maintained in a RPMI 1640 culture medium (Sigma-Aldrich) supplemented with 10% heat-
inactivated foetal calf serum (Gibco), 2 mM L-Glutamine (Gibco), 100 U/ ml penicillin 
(Gibco) and 100 µg/ ml streptomycin (Gibco). YAC-1 cells also received 50 mM 2-
marcaptoethanol (Sigma) in culture medium. Both cell lines were cultured in 25 cm
2
 culture 
flasks (BD Falcon) at 37 °C in an atmosphere of 5% CO2 and 95% air. Cell viability was 
determined by trypan blue dye exclusion assay.  
 
Mouse lung tumor model 
Orthotopic lung tumors were induced by i.v. injection of human non-small cell lung cancer 
(NSCLC) A549 tumor cells (5x10
6
 cell/ mouse) in 200 µL of AIM V media (Life 
Technologies). Mice were maintained in a specific pathogen-free facility and monitored for 
weight loss or any clinical symptom on daily basis. Lung tumor lesions were allowed to grow 
for 2 weeks.  
After 2 weeks, mice were divided into two groups: (i) mice treated with irradiation (n=15), 
and (ii) control mice without irradiation (n=15). One day before the administration of 
radiolabeled murine NK cells, irradiated mice group treated with 2.4 Gy whole-body 
irradiation using an X-ray source (X-RAD 320, Precision X-Ray, USA).
11
 According to the 
directions of the IACUC and Dutch national regulations, all mice were maintained under 
‘irradiation care protocol’ from one week prior to irradiation, until the end of the study. 
Thus, the mice received high energy breeding diet and sterile water with neomycin and 
sucrose to prevent any severe morbidity and mortality that may occur as any side effect of the 
irradiation procedure.  
 
Murine NK cell isolation 
NK cell isolation was performed by positive selection of murine NK cells using magnetic 
MicroBeads. Single cell suspension of splenocytes was prepared at 4 ºC by manual grinding 
of spleens obtained from female Scid-Tg(FCGR3A)Blt transgenic mice (8-10 weeks) 
followed by filtration using 70 micrometre cell strainer (BD Biosciences) to remove any cell 
clump in the cell suspension. Splenocytes were labeled with CD49b (DX5) magnetic 
MicroBeads (Miltenyi Biotec GmbH) and subsequently passed through a MACS
®
 Column in 
the magnetic field of a MACS
®
 Separator (Miltenyi Biotec GmbH). The cells labeled with 
CD49b (DX5) magnetic MicroBeads were retained on the column and unlabeled cells ran 
through the column. Finally, the column was removed from the magnetic field and magnetic 
MicroBeads labeled CD49b (DX5) positive NK cells were eluted.   
Isolated murine NK cells were assessed for viability by the trypan blue exclusion test. 
Fluorescence-activated cell sorting (FACS, Calibur, BD Biosciences) analysis using different 
combinations of fluorescent labeled antibodies was performed to evaluate the purity (NKp46 
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+ CD49b and CD49b + huCD16 positive), maturation (NKp46 + CD11b and NKp46 + CD27 
positive), activation (NKp46 + CD107α positive) and exhaustion (NKp46 + PD-1 positive) of 
murine NK cells after the isolation procedure. 7-amino-actinomycin D (7-AAD, 
eBiosciences) viability solution was used for the exclusion of non-viable cells in FACS 
analysis. Kaluza 1.2 flow cytometry analysis software (Beckman Coulter Inc.) was used for 
FACS data analysis. 
The possibility of ex-vivo NK cell expansion (obtained from C57BL/6 mice) was investigated 
in presence of recombinant murine IL-15 (R&D systems). But, we found altered expression 
levels of various cell receptors; therefore we decided to use freshly purified NK cells, without 
ex-vivo expansion (see supporting information). 
 
Ex-vivo 
111
In-oxine labeling of murine NK cells 
Different labeling buffers, including phosphate buffered saline (PBS, pH 7.4); Tris-HCl; 
0.9% saline + 25% human serum albumin (HSA); RPMI + 10% FCS; RPMI; and RPMI + 
10% HEPES Buffer were evaluated to optimize the labeling conditions. Purified murine NK 
cell suspensions were washed 3 times with buffer solution and incubated with 
111
Indium-8-
hydroxyquinoline (
111
In-oxine,  half-life= 67h, gamma energy= 171/245 keV) from a ready-
to-use radiopharmaceutical vial (Mallinckrodt Medical B.V., Netherlands) in a final volume 
of 1 ml at 37 ºC. Various incubation periods (from 5 to 30 min) were tested. During 
incubation the cell suspension was gently swirled periodically to avoid cell sedimentation. 
After incubation, centrifugation was performed to obtain a radiolabeled cell pellet that was 
washed 3 times with 5 ml buffer solution. The cell pellet containing radiolabeled murine NK 
cells and the supernatant containing unbound 
111
In-oxine were counted separately in an 
automated gamma counter (LKB-Wallac, Finland) and the labeling efficiency (%LE, i.e. 
radioactivity incorporated to the cells) was calculated. After the radiolabeling procedure, cell 
viability was again assessed by the trypan blue exclusion test.  
For ex-vivo stability evaluation, we radiolabeled 1 million murine NK cells with 0.011 MBq 
of 
111
In-oxine and incubated in 96 well plates with PBS (pH 7.4) at 37 ºC. After regular time-
intervals, cells were harvested by centrifugation, and gamma counting of cell pellet and 
supernatant was performed to calculate % release of the radiolabel from labeled NK cells.  
 
51
Cr release assay for 
111
In-oxine labeled murine NK cells 
A chromium-51 (
51
Cr) release assay was performed to evaluate whether the cytotoxic activity 
of the NK cells is maintained after the radiolabeling procedure. In this assay, 
51
Cr labeled 
murine lymphoma YAC-1 cells were used as ‘target cells’ and freshly purified 
111
In-oxine 
labeled or unlabeled (control) murine NK cells were used as ‘effector cells’. YAC-1 cells 
were labeled with 3.7 MBq of 
51
Cr (half-life 27.7 days, gamma energy 320 keV) from a 
ready-to-use radiopharmaceutical vial (Mallinckrodt Medical B.V., Netherlands) for 1 hour 
and 30 minute at 37 ºC in an incubator  with a 5% CO2 and 95% air atmosphere. In 96-well 
‘V’ bottom plates, 1 x 10
3
 YAC-1 cells (target) per well were plated in triplicate, purified 
labeled or unlabeled murine NK cells (effector) were added in different ratios of effector and 
target cells (i.e. 25:1, 6:1, 1.5:1, 0.5:1, 0:1). For spontaneous release, target cells were 
incubated without effector cells in assay medium alone. Plates were centrifuged at 460 g for 3 
Page 6 of 24
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min and incubated for 8 hours at 37 ºC in an atmosphere with 5% CO2 and 95% air.
12
 After 
the incubation period, supernatant and cell pellet were collected separately and counted in an 
automated gamma counter to determine the specific lysis of
 51
Cr labeled YAC-1 cells (target). 
The percentage of specific lysis was calculated as follows:  
= 100 x [(experimental release - spontaneous release) / (total release- spontaneous release)].
13
 
Results are presented as percent 
51
Cr release (specific lysis) for the indicated type of murine 
NK cell (labeled or unlabeled) to tumor cell ratio.  
We also evaluated change in CD107α expression by FACS analysis, to correlate the cytotoxic 
activity levels of NK cells observed in 
51
Cr release assay with the expression of CD107α, 
which is activation marker of NK cells. 
 
Physiological distribution of labeled murine NK cells in SCID mice 
We performed an ex-vivo organ counting assay to evaluate the physiological biodistribution 
of 
111
In-oxine labeled murine NK cells. In this experiment, we aim to differentiate between 
111
In inside NK cells and 
111
In that released from the cells after labelling. We left the 
111
In-
oxine labelled cells in culture media at room temperature and collected the supernatant after 
centrifugation at 1500g for 5 mins to avoid any cells or cell debris contamination, i.e. 
released 
111
In. However, we did not evaluate the nature of radioactivity present in the 
supernatant. Male CB17/Icr-Prkdc
scid
/IcrlcoCrl mice (8-10 weeks) were acclimatised for one 
week in a pathogen-free facility, without prophylactic antibiotics. Mice had access to 
sterilized food and water ad libitum.
14 
One million freshly isolated, 
111
In-oxine labeled 
murine NK cells were intravenously (i.v.) injected in one group of mice (n= 3), while the 
second group of mice (n=3) received released 
111
In. At 24 hour post-injection (p.i.), all mice 
were sacrificed and major organs and tissues were collected (blood, urine, bladder, heart, 
trachea, lung, thymus, liver, spleen, stomach, pancreas, small bowel, large bowel, kidneys, 
fat, muscle, bone, and brain) and weighed. Radioactivity in these tissues was measured in an 
automated gamma counter. Organ radioactivity is represented as standardized uptake value 
(SUV), using the formula: [(tissue activity concentration (MBq/g)]/ [(injected dose (MBq)/ 
body weight (g)].  
 
Biodistribution studies in orthotopic A549 human lung tumor mice 
Male CB17/Icr-Prkdc
scid
/IcrlcoCrl mice (8-10 weeks) were housed in individually ventilated 
cages (IVC) for one week for acclimatisation. To assess murine NK cell trafficking towards 
lung tumor lesions in the orthotopic A549 human lung tumor mouse model, we performed an 
ex-vivo organ counting assay. To evaluate the possibility of interference with autologous 
murine NK cells, in the biodistribution of adoptively transferred NK cells, we performed 
whole-body irradiation and compared the results with non-irradiated mice group.  
Both groups (irradiated and non-irradiated) of mice were i.v. injected with about 1x10
6
 
freshly isolated 
111
In-oxine labeled murine NK cells. Mice were sacrificed at 6h, 24h and 72h 
p.i. (n= 5 per group for each time point), major organs and tissues were collected (as stated 
above), weighed and radioactivity in the samples was measured in an automated gamma 
counter. Organ radioactivity was represented as SUV. Based on visual inspection of the lungs, 
a semi-quantitative score was given to lung tumor burden: i.e. Score 1 for <25% lung covered 
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with tumor nodules, Score 2 for ~50% lung covered with tumor nodules, and Score 3 for 
>75% lung covered with tumor nodules. Lung tissue was collected in formalin for further 
analysis by histology. 
To evaluate the effect of irradiation alone an additional group of orthotopic A549 lung tumor-
bearing mice without administration of radiolabeled murine NK cells (n=5) was sacrificed at 
72h after 2.4 Gy whole-body irradiation. Histology of lung tissue samples was performed. 
 
Histology 
To evaluate the status of lung tumor lesions, we performed histology of tissues samples from 
different groups of mice. In brief, organs were stored in formalin vials and paraffin-
embedded. Five micrometre sections of lung tissues were freed of paraffin, stained with 
haematoxylin and eosin (H&E) and examined by microscopic evaluation. 
 
Statistical analysis 
Quantitative variables are expressed as mean ± standard deviation (SD). The Student’s t test 
for independent samples was used to compare the physiological distribution of 
111
In-oxine 
labeled murine NK cells versus released 
111
In, and to compare the 
111
In labeled murine NK 
cells uptake in different organs in irradiated versus non-irradiated mice groups. Statistical 
significance was set at p<0.05. 
 
RESULTS 
 
Murine NK cell isolation 
FACS analysis with the 7-AAD viability solution confirmed that a high proportion of viable 
murine NK cell population (>95%) was isolated from transgenic Scid-Tg(FCGR3A)Blt mice 
spleens using the anti-CD49b (DX5) micro-beads positive isolation method. FACS analysis 
demonstrated that isolated murine NK cells were >95% pure (NKp46 + CD49b and CD49b + 
huCD16 positive), >93% mature (NKp46 + CD11b and NKp46 + CD27 positive), ~70% 
activated (NKp46 + CD107α positive) and only ~7% exhausted (NKp46 + PD-1 positive). 
 
Ex-vivo 
111
In-oxine labeling of murine NK cells 
The optimal LE (>25%) without affecting the cell viability was achieved using 0.011 MBq of 
111
In-oxine per million purified murine NK cells. Higher amounts of radioactivity resulted in 
a substantial loss of viability of NK cells. PBS (pH 7.4) buffer and a 20-min incubation 
period provided the best labeling conditions (Figure 1a). The ex-vivo stability assay 
demonstrated a release of ~30% label during >5h incubation period in PBS buffer (pH 7.4) at 
37 ºC (Figure 1b).   
 
51
Cr release assay for 
111
In-oxine labeled murine NK cells 
Both 
111
In-oxine labeled and unlabeled (control) murine NK cells demonstrated cytotoxic 
activity in the 
51
Cr release assay. No significant difference in the cytotoxic activity level (p 
>0.1), i.e. percentage of specific lysis, was observed in 
111
In-oxine labeled cells in 
comparison to unlabeled murine NK cells (Figure 2a). The FACS analysis results of murine 
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NK cells that revealed an up-regulated expression of the activation marker CD107α in 
111
In-
oxine labeled cells in comparison to unlabeled murine NK cells (89.3% + 2.4% versus 70%  
+ 1%, p= 0.009, Figure 2b) already before the start of the 
51
Cr release assay (Figure 2c). 
 
Physiological distribution of labeled murine NK cells in SCID mice  
Biodistribution studies in SCID mice demonstrated that at 24h p.i. 
111
In-oxine labeled murine 
NK cells mainly accumulate in the spleen, and to a lesser extent in the liver (Figure 3). In 
contrast, released 
111
In showed significantly lower uptake in spleen and liver (7.0 + 3.5 versus 
120 + 40 and 3.0 + 1.2 versus 21.9 + 2.0, respectively) and was mainly excreted from the 
body via the kidneys into the urine (2.13 + 0.42 versus 0.60 + 0.14). Low lung uptake of 
111
In-oxine labeled cells (1.22 + 0.22) suggested negligible damage to the murine NK cells 
during the isolation and/or labeling procedure. 
 
Biodistribution studies in orthotopic A549 human lung tumor mouse model 
Non-irradiated orthotopic lung tumor-bearing mice demonstrated higher uptake at 6h after 
injection of 
111
In-oxine labeled murine NK cells in comparison with irradiated mice (1.93 + 
0.42 versus 1.07 + 0.6; p=0.06). Both irradiated and non-irradiated mice groups demonstrated 
higher lung uptake at 24h p.i. in comparison with mice without lung tumors (2.07 + 0.30, 
1.51 + 0.54 and 1.22 + 0.22 for irradiated tumor-bearing mice, non-irradiated tumor-bearing 
mice and control mice, respectively). In irradiated mice, lung tumor uptake of 
111
In-oxine 
labeled murine NK cells decreased between 24h and 72h (2.07 + 0.30 versus 1.15 + 0.39; 
p=0.01) (Figure 5a). This decrease in tumor uptake was accompanied by tumor regression 
(score 3 to score 1) (Figure 4, Table 1). In non-irradiated mice, the accumulation of labeled 
murine NK cells in lung tumor remained unchanged during same period, i.e. 24h versus 72h 
(1.51 + 0.54 versus 1.48 + 0.12; p=0.9) (Figure 5b). Unlike irradiated mice, the lung tumor in 
non-irradiated mice did not show major tumor regression (score 3 to score 2/3) (Figure 5c). 
These results were confirmed by histology of lung tissue samples. 
In mice treated with only irradiation without administration of 
111
In-oxine labeled murine NK 
cells, a high tumor burden (score 3) was observed at 72h after irradiation (Figure 6).  
These results are indicating that irradiation in combination with murine NK cell transfer, but 
not irradiation alone, induced an anti-tumor effect in A549 lung tumor bearing mice.  
 
Histology 
H&E staining of lung tissues showed proper tumor growth in 2 weeks duration and 
substantial infiltration of 
111
In-labeled NK cells (Figure 7 a-c).  
H&E staining of lung tissue sections of irradiated and non-irradiated tumor bearing mice 
confirmed that the lung tumor regressed in ‘irradiated and NK cells injected’ mice group at 
72h p.i., while in other groups there was no considerable changes (Figure 8). This data was in 
accordance with our visual semi-quantitative scores for lung tumor burden (showed in Table-
1).   
 
DISCUSSION 
 
Page 9 of 24
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
Until today, researcher were emphasising only on 
111
In labeled human NK cells in their 
research, but none of the study was performed to investigate the opportunity of using 
111
In 
labeled murine NK cells. Therefore, we developed an optimised protocol for 
111
In-oxine 
labeling of murine NK cells, including selection of the ideal buffer solution, accurate amount 
of radioactivity and adequate incubation time. We evaluated six different buffers for 
radiolabeling and ex-vivo stability assay. PBS provided optimal results. A possible 
explanation of this could be that PBS does not contain any proteins that may cause chelation 
of 
111
In-hydroxyquinoline in the reaction mixture. To select the accurate amount of 
radioactivity, we radiolabeled purified murine NK cells with an increasing amount of 
111
In-
oxine. 
111
In-oxine is known for its cytotoxic property at higher concentrations. In this study, 
we also observed a decreasing cell viability pattern with an increasing amount of 
111
In-oxine. 
To select the best incubation time, the labeling efficiency was evaluated at different time 
points. We found that the labeling efficiency increased during the first 20 min. Therefore, this 
time was selected as an adequate incubation time for the radiolabeling procedure. Because 
only a very low dose of 
111
In-oxine was used for the radiolabeling procedure, no loss in the 
biological activity of the murine NK cells was observed. The 
51
Cr release assay demonstrated 
no significant difference in cytotoxic activity between labeled and unlabeled murine NK 
cells. However labeled murine NK cells seemed to become more activated due to isolation 
and radiolabeling procedure and showed a higher expression of CD107α than unlabeled NK 
cells.  
Studies demonstrated that the CD16 receptor that presents in human NK cells is responsible 
for recognizing the Fc domain of therapeutic IgG1 antibodies and mediates Fc related 
immune effectors functions;
23
 therefore we intended to investigate the trafficking of human 
CD16 receptor positive NK cells. For this purpose, we isolated NK cells from Scid-
Tg(FCGR3A)Blt transgenic mice, which are generated to express human CD16 receptor. 
After 
111
In-oxine labeling, we adoptively transfer murine NK cells in the orthotopic A549 
human lung tumor mouse model for biodistribution study. To deplete autologous murine NK 
cells that may interfere with the biodistribution of adoptively transferred NK cells, we 
performed whole-body irradiation using an X-ray source, and compared the results with non-
irradiated mice group. A low X-ray radiation dose, i.e. 2.4 Gy, was used to irradiate the 
mice,
11
 because higher irradiation dose, usually >3 Gy, may cause side-effects in mice such 
as, anaemia, weight loss, infection, intestinal bleeding and incisor damage. We did not 
observe any such health consequences in mice at this radiation dose. The mouse model used 
in the study could be considered as an appropriate model to validate the effect of new 
immune-activating drugs on immune cells, since it provides us a unique opportunity to 
investigate the trafficking of human CD16 receptor positive NK cells in orthotopic human 
tumor mouse model. 
To reduce the number of transgenic mice for the isolation of NK cells, the possibility of ex-
vivo cell expansion was evaluated (see supporting information). Murine NK cells (obtained 
from C57BL/6 mice) expansion in the presence of recombinant murine IL-15 (R&D systems) 
for one week induced cell proliferation and caused activation of the NK cells (i.e. up 
regulation of CD107α and CD69). Furthermore, FACS analysis also revealed altered 
expression levels of various cell receptors that include CD49b, CD27, and PD-1. A similar 
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phenomenon was also observed by other researchers using human NK cells.
24
 We, therefore, 
decided to use freshly purified NK cells, without ex-vivo expansion, for the radiolabeling 
procedure for all in-vivo experiments. 
Experiments to evaluate the physiological biodistribution of 
111
In-oxine labeled murine NK 
cells and released 
111
In revealed that released 
111
In had an entirely different uptake pattern 
than 
111
In-oxine labeled murine NK cells. As expected, 
111
In-oxine labeled murine NK cells 
accumulated mainly in spleen, which was their home organ from where we purified NK cells. 
On the other hand, released 
111
In was mainly excreted via kidneys into urine. Consequently, 
we can exclude the possibility of accumulation of released 
111
In in any target organ of 
interest.  
Biodistribution data revealed a significantly higher uptake of 
111
In-oxine labeled murine NK 
cells in the lungs of mice with orthotopic lung tumors in comparison with control mice, 
which suggests specific migration of the labeled NK cells to the tumor lesions. According to 
the ‘EANM guidelines for the labeling of leucocytes with 
111
In-oxine’
16
 diffuse retention of 
111
In labeled cells in lungs is an indication of cell damage as a result of the labeling 
procedure. We did not find such uptake in the lungs of control animals, indicating that the 
labeled murine NK cells had remained intact during labeling. Moreover, our data 
demonstrated a higher activity in spleen than in liver, which is another measure to 
demonstrate cell integrity after labeling. According to the same EANM guidelines, liver 
activity equal to or higher than spleen activity indicates cell damage.
16
 
Biodistribution experiment in irradiated versus non-irradiated mice groups injected with 
111
In-labeled murine NK cells demonstrated a significant decrease in uptake between 24h and 
72h p.i. in irradiated mice group that was accompanied by tumor regression. Histology data 
of lung tissue sample and visual semi-quantitative scores also confirmed the considerably 
lower lung tumor burden. We did not evaluate the possibility if there is any effect of 
irradiation on normal lung tissue that may contribute in increased uptake. The higher uptake 
in irradiated group could be associated with the fact that the irradiation process could have 
provoked some stress or damage to tumour or normal lung tissue cells, which might have 
triggered the migration of the adoptively transferred labeled NK cells. In contrast, non-
irradiated mice injected with murine NK cells and irradiated mice that were not injected with 
NK cells did not demonstrated such decrease in uptake and/or tumor regression at 72h p.i., 
which was confirmed by histological data. This could be because of the negative effect of the 
residual NK cells against the adoptive infused labeled NK cells in the non-irradiated mice 
group; and due to negligible circulating immune cells in irradiated mice group that were not 
injected with labeled NK cells.  Therefore, our data indicates that irradiation in combination 
with murine NK cell administration, but not irradiation or NK cell administration alone, 
induced a remarkable anti-tumor effect. This study demonstrated application of murine 
111
In- 
labelled NK cells for ex-vivo biodistribution studies, however this could also be associated 
with therapeutic effects when combined with irradiation. Other indirect imaging approaches, 
including tracer dose of radiolabeled antibody or peptide, may not need irradiation and have 
negligible coincidental therapeutic effects. Nevertheless, while extrapolating mice data to 
humans, we should also consider that cancer induced in mice could be in a different 
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microenvironment than those we observe in human patients and that the host response to 
cancer could be different in humans.  
 
CONCLUSIONS 
 
This study demonstrated that isolation and radiolabeling of murine NK cells with 
111
In-oxine 
is feasible without affecting their viability and functionality, provided that only low doses of 
radioactivity are used. We also describe a method to evaluate the biodistribution and 
trafficking of murine NK cells, which might be useful for the determination of potential 
effects of immune mediated drugs on NK cell trafficking. Nevertheless, these data also 
demonstrated that care should be taken when applying labeled NK cells in intervention 
studies as they can potentially augment the therapeutic effect of the intervention. 
 
ASSOCIATED CONTENT 
Supporting Information 
 
Data of ex-vivo expansion of NK cells isolated from the spleens of C57BL/6 black mice and 
receptor expression on expanded cells in comparison to freshly isolated murine NK cells. 
This material is available free of charge via the Internet at http://pubs.acs.org. 
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Table 1 
Visual semi-quantitative scores for lung tumor burden in different mice groups 
 
Time point  
Average Score 
Non-irradiated/ 
NK cell injected 
Irradiated/ NK 
cell injected 
Irradiated Only/ without 
NK cell injection 
6 hour 3 3 N/A 
24 hour 3 3 N/A 
72 hour 2/3 1 3 
For Score 1 <25% lung covered with tumor nodules; Score 2 ~50% lung covered with 
tumor nodules; and Score 3 >75% lung covered with tumor nodules. 
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Figure 1 (a)  
Different buffers evaluated for ex-vivo 
111
In-oxine labeling (mean + SD) of murine NK cells 
 
 
Figure 1 (b)  
Percentage of retention of 
111
In-label inside murine NK cells during incubation in PBS (pH 
7.4) at 37ºC 
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Figure 2 (a)  
51
Cr release assay for 
111
In-oxine labeled and unlabeled (control) murine NK cells: a higher 
but non-significant (p >0.1, mean + SD) cytotoxic activity level was observed in 
111
In-oxine 
labeled cells. 
 
Figure 2 (b)  
Expression of CD107α (mean + SD) in murine NK cells determined by FACS analysis (* p-
value <0.01)  
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Figure 2 (c)  
Representative dot plots indicating expression of CD107α (mean + SD) in murine NK cells 
(NKp46
+
 CD107α
+
 cells) determined by FACS analysis 
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Figure 3  
Biodistribution study in SCID mice injected with either 
111
In-oxine labeled murine NK cells 
or 
111
In released from labeled murine NK cells at 24h p.i. (* p-value <0.02, Avg SUV + SD) 
 
 
 
Figure 4  
Representative images of visual semi-quantitative scores for lung tumor burden  
 
 
 
 
 
 
 
 
 
 
Score: 1 Score: 2 Score: 3 
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Figure 5  
Biodistribution study in (a) irradiated and (b) non-irradiated SCID mice injected with 
111
In-
oxine labeled murine NK cells (c) comparison only in lung tissue (* p value = <0.05 - 24h Vs 
72h; ** p value= <0.05 - 6h Vs 24h Vs 72h; Avg SUV + SD) 
 
(a) 
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(b) 
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(c) 
 
 
Figure 6  
Representative images of lung of same mouse of only irradiation (without 
111
In-oxine labeled 
NK cells administration) group showing high tumor burden (score 3). 
  
 
 
 
Figure 7  
(a) Orthotopic lung tumor and their H&E staining at (b) 5x, and (c) 40x magnification, red 
arrow represents the infiltrating lymphocytes (red arrows) in tumor regions. 
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Figure 8  
H&E staining of lung tissue sections of irradiated and non-irradiated tumor bearing mice 
confirmed that the lung tumor was regressed in irradiated mice group at 72h p.i. while in 
other mice groups it was unaffected. 
 
 Irradiated mice group (20x) Non-irradiated mice group (20x) 
6h 
  
24h 
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